“…Vinorelbine, first prepared and characterized in 1979 by Potier and co-workers [1], has been demonstrated significant clinical activities against nonsmall cell lung cancer, bronchial, adenocarcinoma, breast cancer, and head/neck squamous cell carcinoma. Moreover, it has been widely employed in combination with cisplatinum with or without 5-fluorouracil for the treatment of lung cancer and head/neck carcinomas [2,3].…”